Achilles Therapeutics plc (698.MU)

Compare

1.3600

0.0000

(0.00%)

At close: March 25 at 8:08:59 AM GMT+1

Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration

LONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and its intent to deregister its ADSs from the Securities and Exchange Commission (SEC) under Section 12(b) of the Securities Exchange Act of 1934 (Exchange Act). As previously reported, the Company has called a General Meeting for

GlobeNewswire last month

ACHL
February 2025's Promising Penny Stocks On US Exchanges

As of February 2025, the U.S. stock market is experiencing a positive shift, with major indices like the S&P 500 and Nasdaq Composite seeing gains as investors react to tariff news and a series of earnings reports. Amidst this backdrop, penny stocks continue to capture attention for their potential growth opportunities despite being considered an outdated term. These smaller or newer companies can offer significant returns when supported by robust financial health, making them an intriguing...

Simply Wall St. last month

DC

DC-WT

ACHL
Achilles Therapeutics sells technology assets to AstraZeneca for $12M

Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca (AZN). TRACERx, led by Professor Charles Swanton at University College London, UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over

TipRanks 3 months ago

AZN

AZNCF

ACHL
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (LSE/STO/Nasdaq: AZN). TRACERx (TRAcking Cancer Evolution through therap

GlobeNewswire 3 months ago

ACHL
US Penny Stocks To Watch In November 2024

As U.S. markets navigate a mix of earnings reports and geopolitical developments, investors are keenly watching how these factors influence major indices like the Dow Jones, S&P 500, and Nasdaq Composite. For those interested in exploring investment opportunities beyond the usual blue-chip stocks, penny stocks present a unique avenue worth considering. Despite their somewhat outdated moniker, penny stocks can offer significant growth potential when backed by solid financial fundamentals.

Simply Wall St. 4 months ago

ACHL

GRNQ
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024. The transfer of the Company's lis

GlobeNewswire 4 months ago

ACHL
Achilles Therapeutics Reports Third Quarter 2024 Financial Results

– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 – LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates. Corporate Updates Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has enga

GlobeNewswire 4 months ago

ACHL
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Zacks 6 months ago

ACHL

BFLY-WS
Achilles Therapeutics Announces Strategic Update

–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials. The Company will refocus its strategy to explore further engagement with third parties who are developi

GlobeNewswire 6 months ago

ACHL
Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 7 months ago

ACHL
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GL

GlobeNewswire 7 months ago

ACHL
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with

GlobeNewswire 10 months ago

ARCT

ACHL
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the NoticeLONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on May 16, 2024 from the Nasdaq Stock Market LLC (“Nasdaq”) that

GlobeNewswire 10 months ago

ACHL
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid t

GlobeNewswire 10 months ago

ACHL

Performance Overview

Return	698.MU	MSCI WORLD (^990100-USD-STRD)
YTD	+23.64%	-10.29%
1-Year	+60.00%	-2.24%
3-Year	-50.36%	+10.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Achilles Therapeutics plc (698.MU)

Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration

February 2025's Promising Penny Stocks On US Exchanges

Achilles Therapeutics sells technology assets to AstraZeneca for $12M

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

US Penny Stocks To Watch In November 2024

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?

Achilles Therapeutics Announces Strategic Update

Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Performance Overview